NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

• LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization
• The study is currently enrolling in dose escalation
• Poster to be presented June 2, 2025, 1:30 pm-4:30 pm CT
  
  

BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The Phase 1 study is evaluating LNCB74 as monotherapy in participants with advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer. The trial includes dose escalation and dose expansion and optimization phases. The study is currently enrolling in dose escalation.

"B7-H4 represents an attractive target for ADC therapy given its high expression in multiple tumor types and limited expression in normal tissues," said Udayan Guha, M.D., Ph.D., chief medical officer of NextCure. "LNCB74 has demonstrated a superior safety profile in preclinical studies and potent anti-tumor activity across multiple models, making it a promising therapeutic candidate for patients with B7-H4-expressing solid tumors."

Details of the presentation are as follows:

Title A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4

Targeted Antibody-Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumor

Date and Time: June 2, 2025, 1:30 pm-4:30 pm CT

Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract Number: TPS3167

About NextCure, Inc.



NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.

Cautionary Statement Regarding Forward-Looking Statements



Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries

Timothy Mayer, Ph.D.

NextCure, Inc.

Chief Operating Officer

(240) 762-6486